Literature DB >> 21424325

The Alpha-1 Association Genetic Counseling Program: an innovative approach to service.

Dawn McGee1, Charlie Strange, Rebecca McClure, Laura Schwarz, Marlene Erven.   

Abstract

In an era of specialty medicine, genetic counselors are becoming increasingly focused in their service provision. The Alpha-1 Association Genetic Counseling Program, established in September 2007, specializes in confidential toll-free genetic counseling provided by a certified genetic counselor for Alpha-1 Antitrypsin deficiency, a co-dominant condition associated with lung and/or liver disease. The program received more than 600 callers in its first 2 years. Sixty-seven percent of new callers were family members, carriers, or health professionals. The number of callers increased between the first 2 years, with the greatest increases being family members and health professionals. Testing options and explanation of results encompassed 60% of initial reasons for calls. Seventy-two percent of referrals came from family and friends, test result letters, and the Alpha-1 Association. Between year 1 and 2 family member referrals showed the largest increase. This disease-specific genetic counseling program provides a model that may be useful for other rare disease communities.

Entities:  

Mesh:

Year:  2011        PMID: 21424325     DOI: 10.1007/s10897-011-9355-z

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  14 in total

1.  American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2003-10-01       Impact factor: 21.405

2.  Genetic testing for alpha1-antitrypsin deficiency.

Authors:  Charlie Strange; Ryan Dickson; Cindy Carter; Matthew J Carpenter; Brian Holladay; Ryan Lundquist; Mark L Brantly
Journal:  Genet Med       Date:  2004 Jul-Aug       Impact factor: 8.822

3.  Commentary: What Is and Is Not Telephone Counseling?

Authors:  V O Wang
Journal:  J Genet Couns       Date:  2000-02       Impact factor: 2.537

4.  Recommendations for Telephone Counseling.

Authors:  K E Ormond; J Haun; L Cook; D Duquette; C Ludowese; A L Matthews
Journal:  J Genet Couns       Date:  2000-02       Impact factor: 2.537

5.  Serpin peptidase inhibitor clade A member 1 (SerpinA1) is a novel biomarker for progression of cutaneous squamous cell carcinoma.

Authors:  Mehdi Farshchian; Atte Kivisaari; Risto Ala-Aho; Pilvi Riihilä; Markku Kallajoki; Reidar Grénman; Juha Peltonen; Taina Pihlajaniemi; Ritva Heljasvaara; Veli-Matti Kähäri
Journal:  Am J Pathol       Date:  2011-07-01       Impact factor: 4.307

6.  Results of a survey of patients with alpha-1 antitrypsin deficiency.

Authors:  Charlie Strange; James K Stoller; Robert A Sandhaus; Ryan Dickson; Gerard Turino
Journal:  Respiration       Date:  2005-08-03       Impact factor: 3.580

7.  Assessment of the Effectiveness of Genetic Counseling by Telephone Compared to a Clinic Visit.

Authors:  Karan K Sangha; Anita Dircks; Sylvie Langlois
Journal:  J Genet Couns       Date:  2003-04       Impact factor: 2.537

8.  Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem.

Authors:  James K Stoller; Robert A Sandhaus; Gerard Turino; Ryan Dickson; Keith Rodgers; Charlie Strange
Journal:  Chest       Date:  2005-10       Impact factor: 9.410

9.  Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial.

Authors:  Beth N Peshkin; Tiffani A Demarco; Kristi D Graves; Karen Brown; Rachel H Nusbaum; Diana Moglia; Andrea Forman; Heiddis Valdimarsdottir; Marc D Schwartz
Journal:  Genet Test       Date:  2008-03

10.  Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America.

Authors:  F J de Serres; I Blanco; E Fernández-Bustillo
Journal:  Clin Genet       Date:  2003-11       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.